

**Texas Prior Authorization Program  
Clinical Criteria**

---

**Drug/Drug Class**

**Anxiolytics and Sedatives/Hypnotics (ASHs)**

- **Anxiolytics – Buspirone (Revised)**

**Note:** Click the hyperlink to navigate directly to that section.

**Clinical Criteria Information Included in this Document**

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical criteria
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical criteria rules
- **Logic diagram:** a visual depiction of the clinical criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable
- **References:** clinical publications and sources relevant to this clinical criteria

**Revision Notes**



## Anxiolytics and Sedatives/Hypnotics (ASHs)

### Anxiolytics – Buspirone Drugs Requiring Prior Authorization

Drugs Requiring Prior Authorization	
Label Name	GCN
BUSPIRONE HCL 5 MG TABLET	28890
BUSPIRONE HCL 7.5 MG TABLET	13037
BUSPIRONE HCL 10 MG TABLET	28891
BUSPIRONE HCL 15 MG TABLET	28892
BUSPIRONE HCL 30 MG TABLET	92121



## Anxiolytics and Sedatives/Hypnotics (ASHs)


### Anxiolytics – Buspirone Clinical Edit Criteria Logic

1. Is the client less than (<) 6 years of age?  
 Yes (Deny)  
 No (Go to #2)
  
2. Does the client have a diagnosis of generalized anxiety disorder (GAD) or panic disorder in the last 730 days?  
 Yes (Go to #3)  
 No (Deny)
  
3. Has the client had 1 claim for a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI) in the last 180 days?  
 Yes (Approve – 120 days)  
 No (Deny)



# Anxiolytics and Sedatives/Hypnotics (ASHs)

## Anxiolytics – Buspirone Clinical Edit Criteria Logic Diagram





## Anxiolytics and Sedatives/Hypnotics (ASHs)

### Clinical Edit Criteria Supporting Tables

<b>Step 2 (diagnosis of anxiety disorder)</b>	
<b>Required diagnosis: 1</b>	
<b>Look back timeframe: 730 days</b>	
<b>ICD-10 Code</b>	<b>Description</b>
F064	ANXIETY DISORDER DUE TO KNOWN PHYSIOLOGICAL CONDITION
F064	ANXIETY DISORDER DUE TO KNOWN PHYSIOLOGICAL CONDITION
F419	ANXIETY DISORDER, UNSPECIFIED
F419	ANXIETY DISORDER, UNSPECIFIED
F410	PANIC DISORDER [EPISODIC PAROXYSMAL ANXIETY] WITHOUT AGORAPHOBIA
F410	PANIC DISORDER [EPISODIC PAROXYSMAL ANXIETY] WITHOUT AGORAPHOBIA
F411	GENERALIZED ANXIETY DISORDER
F411	GENERALIZED ANXIETY DISORDER
F413	OTHER MIXED ANXIETY DISORDERS
F413	OTHER MIXED ANXIETY DISORDERS
F418	OTHER SPECIFIED ANXIETY DISORDERS
F418	OTHER SPECIFIED ANXIETY DISORDERS
F409	PHOBIC ANXIETY DISORDER, UNSPECIFIED
F409	PHOBIC ANXIETY DISORDER, UNSPECIFIED
F4001	AGORAPHOBIA WITH PANIC DISORDER
F4001	AGORAPHOBIA WITH PANIC DISORDER
F4002	AGORAPHOBIA WITHOUT PANIC DISORDER
F4002	AGORAPHOBIA WITHOUT PANIC DISORDER
F4000	AGORAPHOBIA, UNSPECIFIED
F4000	AGORAPHOBIA, UNSPECIFIED
F4011	SOCIAL PHOBIA, GENERALIZED
F4011	SOCIAL PHOBIA, GENERALIZED
F4010	SOCIAL PHOBIA, UNSPECIFIED
F4010	SOCIAL PHOBIA, UNSPECIFIED
F40218	OTHER ANIMAL TYPE PHOBIA
F40218	OTHER ANIMAL TYPE PHOBIA
F40230	FEAR OF BLOOD
F40230	FEAR OF BLOOD
F40210	ARACHNOPHOBIA

<b>Step 2 (diagnosis of anxiety disorder)</b>	
<b>Required diagnosis: 1</b>	
<b>Look back timeframe: 730 days</b>	
F40210	ARACHNOPHOBIA
F40233	FEAR OF INJURY
F40233	FEAR OF INJURY
F40220	FEAR OF THUNDERSTORMS
F40220	FEAR OF THUNDERSTORMS
F40228	OTHER NATURAL ENVIRONMENT TYPE PHOBIA
F40228	OTHER NATURAL ENVIRONMENT TYPE PHOBIA
F40242	FEAR OF BRIDGES
F40242	FEAR OF BRIDGES
F40231	FEAR OF INJECTIONS AND TRANSFUSIONS
F40231	FEAR OF INJECTIONS AND TRANSFUSIONS
F40232	FEAR OF OTHER MEDICAL CARE
F40232	FEAR OF OTHER MEDICAL CARE
F40290	ANDROPHOBIA
F40290	ANDROPHOBIA
F40240	CLAUSTROPHOBIA
F40240	CLAUSTROPHOBIA
F40241	ACROPHOBIA
F40241	ACROPHOBIA
F408	OTHER PHOBIC ANXIETY DISORDERS
F408	OTHER PHOBIC ANXIETY DISORDERS
F40243	FEAR OF FLYING
F40243	FEAR OF FLYING
F40248	OTHER SITUATIONAL TYPE PHOBIA
F40248	OTHER SITUATIONAL TYPE PHOBIA
F40291	GYNEPHOBIA
F40291	GYNEPHOBIA
F40298	OTHER SPECIFIED PHOBIA
F40298	OTHER SPECIFIED PHOBIA

<b>Step 3 (history of an SSRI or SNRI)</b>	
<b>Required number of claims: 1</b>	
<b>Look back timeframe: 180 days</b>	
<b>GCN</b>	<b>Description</b>
34876	BRISDELLE 7.5MG CAPSULE
16345	CELEXA 10MG TABLET

<b>Step 3 (history of an SSRI or SNRI)</b> <b>Required number of claims: 1</b> <b>Look back timeframe: 180 days</b>	
<b>GCN</b>	<b>Description</b>
16342	CELEXA 20MG TABLET
16343	CELEXA 40MG TABLET
16345	CITALOPRAM HBR 10MG TABLET
16344	CITALOPRAM HBR 10MG/5ML SOLUTION
16342	CITALOPRAM HBR 20MG TABLET
16343	CITALOPRAM HBR 40MG TABLET
23161	CYMBALTA 20MG CAPSULE
23162	CYMBALTA 30MG CAPSULE
23164	CYMBALTA 60MG CAPSULE
34482	DESVENLAFAXINE ER 100MG TABLET
35584	DESVENLAFAXINE ER 100MG TABLET
34470	DESVENLAFAXINE ER 50MG TABLET
35582	DESVENLAFAXINE ER 50MG TABLET
23161	DULOXETINE HCL DR 20MG CAPSULE
23162	DULOXETINE HCL DR 30MG CAPSULE
23164	DULOXETINE HCL DR 60MG CAPSULE
16818	EFFEXOR XR 150MG CAPSULE
16816	EFFEXOR XR 37.5MG CAPSULE
16817	EFFEXOR XR 75MG CAPSULE
17851	ESCITALOPRAM 10MG TABLET
17987	ESCITALOPRAM 20MG TABLET
18975	ESCITALOPRAM 5MG TABLET
19035	ESCITALOPRAM 5MG/5ML SOLUTION
35335	FETZIMA 20-40MG TITRATION PAK
35334	FETZIMA ER 120MG CAPSULE
35327	FETZIMA ER 20MG CAPSULE
35328	FETZIMA ER 40MG CAPSULE
35329	FETZIMA ER 80MG CAPSULE
16357	FLUOXETINE 20MG/5ML SOLUTION
12929	FLUOXETINE DR 90MG CAPSULE
16353	FLUOXETINE HCL 10MG CAPSULE
16356	FLUOXETINE HCL 10MG TABLET
16354	FLUOXETINE HCL 20MG CAPSULE
16359	FLUOXETINE HCL 20MG TABLET
16355	FLUOXETINE HCL 40MG CAPSULE

<b>Step 3 (history of an SSRI or SNRI)</b>	
<b>Required number of claims: 1</b>	
<b>Look back timeframe: 180 days</b>	
<b>GCN</b>	<b>Description</b>
30817	FLUOXETINE HCL 60MG TABLET
99481	FLUVOXAMINE ER 100MG CAPSULE
99482	FLUVOXAMINE ER 150MG CAPSULE
16349	FLUVOXAMINE MALEATE 100MG TABLET
16347	FLUVOXAMINE MALEATE 25MG TABLET
16348	FLUVOXAMINE MALEATE 50MG TABLET
35584	KHEDEZLA ER 100MG TABLET
35582	KHEDEZLA ER 50MG TABLET
17851	LEXAPRO 10MG TABLET
17987	LEXAPRO 20MG TABLET
18975	LEXAPRO 5MG TABLET
19035	LEXAPRO 5MG/5ML SOLUTION
17078	PAROXETINE CR 12.5MG TABLET
17077	PAROXETINE CR 25MG TABLET
17079	PAROXETINE CR 37.5MG TABLET
16364	PAROXETINE HCL 10MG TABLET
16366	PAROXETINE HCL 20MG TABLET
16367	PAROXETINE HCL 30MG TABLET
16368	PAROXETINE HCL 40MG TABLET
16364	PAXIL 10MG TABLET
16369	PAXIL 10MG/5ML SUSPENSION
16366	PAXIL 20MG TABLET
16367	PAXIL 30MG TABLET
16368	PAXIL 40MG TABLET
17078	PAXIL CR 12.5MG TABLET
17077	PAXIL CR 25MG TABLET
17079	PAXIL CR 37.5MG TABLET
20854	PEXEVA 10MG TABLET
20855	PEXEVA 20MG TABLET
20856	PEXEVA 30MG TABLET
20857	PEXEVA 40MG TABLET
99452	PRISTIQ ER 100MG TABLET
99451	PRISTIQ ER 50MG TABLET
16353	PROZAC 10MG PULVULE
16354	PROZAC 20MG PULVULE



<b>Step 3 (history of an SSRI or SNRI)</b>	
<b>Required number of claims: 1</b>	
<b>Look back timeframe: 180 days</b>	
<b>GCN</b>	<b>Description</b>
16355	PROZAC 40MG PULVULE
12929	PROZAC WEEKLY 90MG CAPSULE
16376	SERTRALINE 20MG/ML ORAL CONCENTRATE
16375	SERTRALINE HCL 100MG TABLET
16373	SERTRALINE HCL 25MG TABLET
16374	SERTRALINE HCL 50MG TABLET
35346	TRINTELLIX 5MG TABLET
35347	TRINTELLIX 10MG TABLET
35349	TRINTELLIX 20MG TABLET
16815	VENLAFAXINE HCL 100MG TABLET
16811	VENLAFAXINE HCL 25MG TABLET
16812	VENLAFAXINE HCL 37.5MG TABLET
16813	VENLAFAXINE HCL 50MG TABLET
16814	VENLAFAXINE HCL 75MG TABLET
16818	VENLAFAXINE HCL ER 150MG CAPSULE
14353	VENLAFAXINE HCL ER 150MG TABLET
14354	VENLAFAXINE HCL ER 225MG TABLET
16816	VENLAFAXINE HCL ER 37.5MG CAPSULE
14349	VENLAFAXINE HCL ER 37.5MG TABLET
16817	VENLAFAXINE HCL ER 75MG CAPSULE
14352	VENLAFAXINE HCL ER 75MG TABLET
29916	VIIBRYD 10MG TABLET
29917	VIIBRYD 20MG TABLET
29918	VIIBRYD 40MG TABLET
31956	VIIBRYD TITRATION PACK
16375	ZOLOFT 100MG TABLET
16376	ZOLOFT 20MG/ML ORAL CONCENTRATE
16373	ZOLOFT 25MG TABLET
16374	ZOLOFT 50MG TABLET



## Anxiolytics and Sedatives/Hypnotics (ASHs)

### Clinical Edit Criteria References

1. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc. 2018. Available at <http://www.clinicalpharmacology.com>. Accessed on April 27, 2018.
2. Micromedex [online database]. Available at [www.micromedexsolutions.com](http://www.micromedexsolutions.com). Accessed on April 27, 2018.
3. 2014 ICD-9-CM Diagnosis Codes, Volume 1. 2014. Available at <http://www.icd9data.com/>. Accessed on January 2, 2015.
4. 2014 ICD-10-CM Diagnosis Codes, Volume 1. 2014. Available at <http://www.icd10data.com/>. Accessed on January 2, 2015.
5. American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2<sup>nd</sup> ed. Washington DC: American Psychiatric Association (APS); 2009 Jan. 90 p. Available at [www.psychiatryonline.org](http://www.psychiatryonline.org). Accessed April 27, 2018.
6. Connolly SD, Bernstein GA, et al. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. *J Am Acad Child Adolesc Psychiatry* 2007;46(2):267-283. Available at [www.aacap.org](http://www.aacap.org). Accessed April 27, 2018. AACAP Clinical Practice Guidelines for the treatment of anxiety are currently in development.
7. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. *Int J Psych Clin Pract* 2012;16:77-84.
8. American Society of Addiction Medicine (ASAM). Public Policy Statement on Measures to Counteract Prescription Drug Diversion, Misuse and Addiction. Adopted January 2012. Available at [www.asam.org](http://www.asam.org). Accessed January 2, 2015.

## Publication History

The Publication History records the publication iterations and revisions to this document. Notes for the *most current revision* are also provided in the **Revision Notes** on the first page of this document.

<b>Publication Date</b>	<b>Notes</b>
04/27/2018	Presented to the DUR Board